Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T Robust Phase 2 IPF and PPF results support development of BMS-986278 across the spectrum of progressive lung fibrosis IPF1 PPF2 Rate of FVC decline ppFVC over 26 weeks³ 0 -0.5 60 mg n=93 30 mg n=91 Placebo n=92 -1 -1.5 -2 -2.5 -3 62% Relative reduction in FVC decline Rate of FVC decline ppFVC over 26 weeks³ 0 -0.5 60 mg 30 mg n=42 -1 -1.5 -2 -2.5 -3 -3.5 69% Relative reduction in FVC decline n=39 " Placebo n=41 -3.5 -4 -4 -4.5 -5 -5.5 Compelling reduction in the decline of lung function at 60 mg in both IPF and PPF cohorts, with a favorable and differentiated tolerability profile 1. Corte TJ, et al. Am J Respir Crit Care Med. 2023;207:A2785. 2. Corte TJ, et al. ERS 2023 [Presentation #RCT800]. 3. Mean +SEM, primary endpoint, linear model with Ill Bristol Myers Squibb™ supplementary estimand Not for Product Promotional Use 59

View entire presentation